Par3 dysfunction may differentially affect tumor outcomes in different tissues depending on tumor origin, tumor microenvironment, tumor type, cell density, cell–cell contact, and the synergy of other tumor-associated signaling pathways. This evidence concerns the gene PARD3 and neoplasm.